Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

NVS

Phase 3

Fabhalta® (iptacopan)

Paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab)

2025

APPULSE-PNH trial. 12/6/24- Topline data reported. To present data at a medical meeting in 2025.

Data readout

SDGR

Phase 1

SGR-2921

Acute myeloid leukemia or myelodysplastic syndrome

H2 2025

12/10/23- Presented preclinical data at ASH '23. Ph1 study initiated. 1/25- Granted orphan drug designation. 2/26/25- Initial clinical data in H2 2025.

Data readout

ITOS

Phase 2

Belrestotug (EOS-448) + Dostarlimab (doublet) + Nelistotug (triplet)

Head and neck squamous cell carcinoma (HNSCC)

2025

TIG-006/GALAXIES H&N-202 trials. Collab w/ GSK. 5/10/24- Enrollment ongoing. Discontinue TIG-006 to focus on GALAXIES H&N-202. 11/12/24- Topline data from 1st portion of TIG-006 in 2025 and interim data from GALAXIES H&N-202 in 2025.

Data readout

CLNN

Phase 2

CNM-Au8

MS (Multiple Sclerosis)

H2 2025

REPAIR-MS study. Enrollment completion in H1 2024. EO Ph2 meeting w/ FDA in mid-2024. 3/24/25- Topline results in H2 2025.

Data readout

NCNA

Phase 1/2

NUC-3373 (ProTide) combo w/ pembrolizumab

Solid Tumors ,Lung cancer

2025

NuTide:303 study. Data at AACR-NCI-EORTC '23. 11/11/24- Reported initial data. 11/25/24- Initiate Ph1/2 expansion study. 3/20/25- Data in 2025.

Data readout

BCRX

Phase 1

BCX17725

Netherton Syndrome

YE 2025

10/02/24- Initiated enrollment. 2/24/25- Initial data by YE 2025.

Data readout

MRUS

Phase 2

Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) in comb w/ SoC

2L mCRC (Metastatic colorectal cancer)

H2 2025

2L CRC cohort. 7/8/24- First patient dosed in Ph2. 2/27/25- Initial clinical data in H2 2025.

Data readout

KURA

Phase 1

KO-2806

Solid tumors, KRASG12C-mutant non-small cell lung cancer

H2 2025

Collab w/ $MRTX. FIT-001 trial. 10/19/23- First patient dosed. 11/2/23- Ongoing dose-escalation trial. 8/24- Began dosing in FIT-001 + adagrasib. 2/28/25- Prelim data in H2 2025.

Data readout

AGIO

Phase 3

PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator)

Sickle Cell Disease

Late 2025

RISE UP trial. 11/02/23- First patient dosed. 12/18/24- Granted orphan medicinal product designation in EC. 1/13/25- Topline data in late 2025 w/ potential US commercial launch in 2026.

Data readout

ARVN

Phase 1

ARV-393

B-cell lymphomas

2025

1/10/25- Present initial data in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20